The Conditions That Travel With ME/CFS — a Series

ME/CFS
Series
Comorbidities
ME/CFS rarely travels alone. Mast cell activation, POTS, hypermobility, fibromyalgia, gut problems, and migraine all co-occur far more often than chance. This is the landing page for a plain-language series on each co-occurring condition: what it is, how it relates to ME/CFS, the treatments, and — always — what it means if the treatment doesn’t work.
Author

Yannick Loth

Published

July 28, 2026

ME/CFS rarely shows up alone. In practice, it travels with a constellation of other conditions — mast cell activation, postural orthostatic tachycardia syndrome (POTS), hypermobility syndromes, small fiber neuropathy, chronic infection, autoimmunity, gut problems, and fibromyalgia-pattern pain. The primary document behind this site calls the tightest cluster of seven the Septad: interacting pathophysiologies that co-occur and feed one another. This series is informed by that idea but a little broader — it covers those seven plus the fibromyalgia-pain pattern, and it closes with a piece on how the amplifiers chain into a single picture.

This series explains one co-occurring condition at a time, in plain language, for a reader who is sick and tired of jargon. Each article follows the same shape:

  1. What it feels like — a short, honest vignette.
  2. What it is — the mechanism, in ordinary words.
  3. How it relates to ME/CFS — including whether it’s a cause, a downstream amplifier, or a coincidental companion (often: amplifier).
  4. The treatments — what they are, how they work.
  5. What it means if the treatment doesn’t work — the honest part.

1 Part 1: Mast Cell Activation and Histamine

The series opens with MCAS — the condition where your immune cells fire without a trigger, flushing and reacting to dust and touch. It’s a natural first entry because it’s common, it’s reversible in part, and it’s emblematic of the whole series’ core message: most of these are amplifiers, not causes, and treating an amplifier can still be worth doing.

Read the three articles in order:

  1. MCAS and ME/CFS: Why Your Body Reacts to Nothing — what MCAS is, why it appears after ME/CFS (not before), and the difference between MCAS-alone and ME/CFS-with-MCAS.
  2. Antihistamines for ME/CFS and MCAS: H1 vs H2, and Why Your Doctor Raises the Dose — the medications, histamine and its receptors, and the stabilisers.
  3. When the Antihistamine Doesn’t Work — normal tests, histamine intolerance, the “flavours” of mast cells, the amplification ratchet, and what to do next.

2 Part 2: Postural Orthostatic Tachycardia (POTS)

The series continues with POTS — the heart that races when you stand, the blood volume that is paradoxically low, and the brain that loses blood flow even when vitals look normal. POTS is the second most common co-occurring amplifier; it directly pairs with the mast-cell orthostatic links and the connective-tissue problems covered next.

Read the two articles in order:

  1. POTS and the Heart That Races When You Stand — what POTS is, the renin-aldosterone paradox, the cerebral blood flow data, and the difference between POTS-alone and ME/CFS-with-POTS.
  2. Treatments for POTS and Dysautonomia in ME/CFS — and What It Means When They Don’t Work — salt, compression, fludrocortisone, midodrine, ivabradine, beta-blockers, pyridostigmine, the SSRI pitfall, expected results, and the honest failure discussion.

3 Part 3: Hypermobility and the Connective-Tissue Connection

The triad comes together: hypermobility completes the POTS–MCAS–hEDS cluster. This two-part entry explains why flexible tissue does not hold together — the five mechanistic pathways, how mast cells can actively degrade collagen (acquired hypermobility), the TNXB genetics, the neurodivergence axis, and the treatment architecture from isometric physiotherapy through circadian collagen support to experimental MMP inhibition.

Read the three articles in order:

  1. Hypermobile EDS and the Connective-Tissue Connection to ME/CFS — what hEDS is, why it has no identified genetic defect, the 81% vs 15.5% gap, acquired progressive hypermobility (tryptase→MMP-3/-13, chymase→MMP-1, histaminylation), the matrix-stiffness feedback loop, five mechanistic pathways, the neurodivergence connection, TNXB genetics, the permanent 10–20% energy tax, and hEDS-alone vs hEDS-on-ME/CFS.
  2. Managing Hypermobility on Top of ME/CFS — isometric resistance protocols, circadian collagen cofactor timing (vitamin C, alpha-ketoglutarate), glycine and proline, copper/B6 for LOX, low-dose doxycycline for MMP-9, emerging therapies (tVNS, HIF-1α inhibitors, TGF-β1 blockade), CCI surgery, expected results, and an example structured trial.
  3. When the Treatment Doesn’t Help — the deconditioning-PEM trap, the matrix-stiffness tipping point, the congenital-vs-acquired triage, the six numbered failure points, falsifiable predictions, and what you can actually do.

4 Part 4: Small Fiber Neuropathy

The series continues with the wiring that is wrong — small fiber neuropathy explains the burning, shooting pain and the autonomic dysfunction that the heart-rate monitors show but standard neurology tests miss.

Read the two articles in order:

  1. Small Fiber Neuropathy — When the Wiring Itself Is Wrong in ME/CFS — what SFN is, the three mechanism families (mast-cell tryptase→PAR2, microvascular ischemia, IgG-mediated DRG autoimmunity), the visceral-vs-somatic distinction, the POTS–SFN–MCAS–hEDS intersection, and SFN-alone vs SFN-on-ME/CFS.
  2. Treating Small Fiber Neuropathy in ME/CFS — gabapentinoids, SNRIs, topicals, IVIG for autoimmune SFN, alpha-lipoic acid, mast-cell stabilisers, expected results, the honest failure discussion, and practical guidance.

5 Part 5: Fibromyalgia-Pattern Pain

The pain that isn’t muscle — when your nervous system turns the gain up, TRPV1 and TRPA1 channels are stuck open, and body heat feels like burning. This overlaps with 47–76% of ME/CFS patients.

Read the two articles in order:

  1. The Pain That Isn’t Muscle — Fibromyalgia-Pattern Pain in ME/CFS — central sensitisation, TRPV1/TRPA1 channels, the COX-2/PGE2 feed-forward loop, the nociplastic-neuropathic hybrid, and fibromyalgia-alone vs fibromyalgia-on-ME/CFS.
  2. Treating Fibromyalgia-Pattern Pain in ME/CFS — LDN, SNRIs, gabapentinoids, COX-2 inhibitors, PEA, NMDA antagonists, expected results, the honest failure discussion, and practical guidance.

6 Part 6: GI Dysmotility and SIBO

The gut that misbehaves — why your stomach empties slowly, how bacteria steal your breakfast, hydrogen sulfide as a mitochondrial poison, and diet as the first lever a patient can pull.

Read the two articles in order:

  1. SIBO, Gastroparesis, and the Gut That Misbehaves in ME/CFS — ICC/vagal motility failure, mast-cell–gut axis, H₂S mitochondrial toxicity, DAO and histamine intolerance, and GI-problems-alone vs GI-problems-on-ME/CFS.
  2. Treating SIBO, Gastroparesis, and the Gut — meal spacing, low-histamine elimination, SIBO antibiotics and herbals, elemental diet, DAO, butyrate, prokinetics, expected results, a structured trial example, the honest failure discussion, falsifiable predictions, and practical guidance.

7 Part 7: Chronic Infection

The infection that never ended — EBV, HHV-6, tick-borne disease, abortive lytic replication, poly-herpesvirus co-reactivation, and why something is still talking to your immune system years after you “recovered.”

Read the two articles in order:

  1. EBV, HHV-6, Tick-Borne Disease, and the Infection That Never Ended in ME/CFS — abortive-lytic-replication model, EBV→mast cell→MMP-9 pathway, HHV-6 miR-aU14→mitochondrial fragmentation, poly-herpesvirus co-reactivation, and chronic-infection-alone vs chronic-immune-stimulation-on-ME/CFS.
  2. Antivirals, Immunomodulators, and What It Means When They Don’t Work in ME/CFS — valacyclovir, valganciclovir, cimetidine, mast-cell stabilisers to intercept the EBV→MMP-9 pathway downstream, why ALR makes antivirals less effective, expected results, the honest failure discussion, and practical guidance.

8 Part 8: Autoimmunity

Antibodies that talk to your nervous system — GPCR autoantibodies targeting your blood vessels, gut, and brain, the Fc-glycoprofile that determines pathogenicity, and why removing them doesn’t always fix the problem.

Read the two articles in order:

  1. GPCR Autoantibodies, Immune Attack on the Nervous System, and the Antibodies That Talk to Your Receptors in ME/CFS — what GPCR autoantibodies are, the 29–91% prevalence range and what it actually means, the Fc-glycoprofile, the post-infectious trigger, and autoimmunity-alone vs autoimmunity-on-ME/CFS.
  2. Immunoadsorption, IVIG, Rituximab, Daratumumab — Removing the Antibodies, and What It Means When That Doesn’t Fix ME/CFS — the treatment evidence from most to least mature, the RituxME lesson, the daratumumab signal, expected results, the honest failure discussion, and practical guidance.

9 Part 9: Chained Together — Synthesis Capstone

How the amplifiers become one disease — the feedback loops connecting all eight conditions, the amplification ratchet that makes longer illness harder to treat, and the clinical imperative of multi-target treatment.

Read the article:

  1. Chained Together: How the Amplifiers Become One Disease in ME/CFS — the vascular-inflammation loop, the nerve-mast-cell amplifier, the gut-brain-histamine axis, the EBV–mast cell–MMP-9–BBB bridge, the autoimmunity–POTS–SFN loop, the amplification ratchet, multi-target treatment, and what the whole series has argued in one place.

10 A note on honesty

Every article in this series distinguishes three things carefully: what is confirmed by evidence, what is a promising hypothesis, and what is an individual patient’s experience. It also keeps the two ME/CFS situations distinct — a co-occurring condition on its own vs the same condition sitting on top of ME/CFS — because the treatment goal and the meaning of a failure usually differ (while acknowledging this is a clinical, judgment-dependent boundary rather than a hard biological wall).

The underlying science is fully cited in the primary document — see the MCAS overviews and the cross-disease chapter for source material if you want the detail behind these plain-language pieces (Loth 2026).

References

Loth, Yannick. 2026. “Myalgic Encephalomyelitis / Chronic Fatigue Syndrome: A Comprehensive Medical Documentation.” https://yannickloth.github.io/health-me-cfs/.